Almirall Aktie [WKN DE: A0MU8Y / ISIN: ES0157097017]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Almirall

11.11.24		Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth (Businesswire)
15.10.24		Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe (Businesswire)
25.09.24		New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis (Businesswire)
23.09.24		Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress (Businesswire)
10.07.24		NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults (Businesswire)
02.07.24		Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030 (Businesswire)
28.06.24		Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1 (Businesswire)
13.05.24		Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio (Businesswire)
13.03.24		Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases (Businesswire)
19.02.24		Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology (Businesswire)
19.02.24		Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business (Businesswire)
21.12.23		Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases (Businesswire)
12.12.23		Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology (Businesswire)
17.11.23		Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis (Businesswire)
14.11.23		Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases (Businesswire)
09.11.23		Almirall’s Nine-month 2023 Results: (Businesswire)
20.10.23		Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years (Businesswire)
13.10.23		Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1 (Businesswire)
11.10.23		Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis (Businesswire)
18.09.23		EBGLYSS® (Lebrikizumab) erhält positive CHMP-Stellungnahme für mittelschwere bis schwere atopische Dermatitis (Businesswire)
15.09.23		EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis (Businesswire)
24.07.23		Almirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business (Businesswire)
07.07.23		Almirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis (Businesswire)
20.06.23		Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing (Businesswire)
13.06.23		Almirall announces the pricing and closing of its €200mm non pre-emptive share capital increase (Businesswire)
12.06.23		Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase (Businesswire)
08.05.23		Almirall’s First Quarter 2023 Results (Businesswire)
01.05.23		Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis (Businesswire)
12.04.23		Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study (Businesswire)
20.02.23		Almirall’s Full-Year 2022 Results (Businesswire)
04.01.23		Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
28.11.22		Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants (Businesswire)
10.11.22		Almirall’s Nine-month 2022 Results (Businesswire)
25.07.22		Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1 (PR Newswire)
09.05.22		Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance (PR Newswire)
21.02.22		Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall (PR Newswire)
21.02.22		Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers (PR Newswire)
15.11.21		Almirall delivers solid nine months 2021 results and tightens its upgraded guidance (PR Newswire)
08.11.21		Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program (PR Newswire)
16.08.21		Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials (PR Newswire)
26.07.21		Almirall delivers robust H1 performance and increases full-year guidance (PR Newswire)
26.07.21		Almirall delivers robust H1 performance and increases full-year guidance (PR Newswire)
20.07.21		Almirall erhält die Zulassung der Europäischen Kommission für Klisyri®▼ (Tirbanibulin), eine innovative topische Behandlung für aktinische Keratosen (PR Newswire)
19.07.21		Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis (PR Newswire)
19.07.21		Almirall receives European Commission approval of Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis (PR Newswire)
06.07.21		Almirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults (PR Newswire)
01.07.21		Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole (PR Newswire)
26.02.18		/C O R R E C T I O N -- Thermi/ (PR Newswire)
26.02.18		Thermi announces new clinical education and enhanced training platforms for clinicians (PR Newswire)
22.02.18		Thermi and Sinclair terminate their collaboration on Silhouette Instalift™ (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Mit Ripple Millionär werden? So klappt’s!

Pierer Mobility-Aktie verliert: Insolvente KTM zahlt Dezember-Gelder doch nicht vorzeitig und stoppt Produktion

Israels Armee: Hamas-Kommandozentrale in Gaza angegriffen

Bitcoin klettert über 107.000 US-Dollar und schafft neues Allzeithoch

Analyst sieht Gründe für noch mehr Optimismus: Bitcoin und Aktienmarkt werden weiter steigen

EZB-Zinsentscheid im Blick: ATX schließt mit Gewinnen -- DAX beendet Handel fester -- US-Märkte letztendlich schwach -- Börsen in Japan und China schließen mit Zuwächsen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	18.12.2024 07:53
Kaufwert:	EUR
	Hinzufügen Speichern